

CLINICAL LEADERSHIP EXECUTIVE OUTBRIEF	
Date of meeting	21 st April 2020
Attendees	Group Triumvirates (Group Directors, Group Directors of Nursing and Group Directors of Operations), Director of Therapies and Executive Directors. Mel Roberts for silver item
Apologies	Sarah Yusuf, Nicky Taylor
Key points of discussion relevant to the Board	<ul style="list-style-type: none"> • COVID-19 Exit and recovery (Gold): The exit and recovery phases were discussed in detail with teams highlighting their key lessons from COVID-19 so far and ambitions for the recovery period. A recognition of some urgency to certain treatments. The key opportunity to remake the BTC was cited. CLE will receive 'future of general practice' advice when it next meets as recovery will be at SWB "primary care led". • COVID-19 Surge and super surge (Silver): The Committee discussed mortality and outcome. Focus on oxygen prescription and saving lives in coming weeks. Need to ensure we manage BAME anxiety among employees and in the community.
Positive highlights of note	<ul style="list-style-type: none"> • 2019/20 financial position: year-end control total met (40k headroom) • Q4 cancer standard met • Strong recruitment recently of surgeons
Matters of concern or key risks to escalate to the Board	<ul style="list-style-type: none"> • Very low presenting volumes for conditions needing urgent care because of lockdown/COVID-19 anxieties
Matters presented for information or noting	<ul style="list-style-type: none"> • IQPR • Chief Executive's report to the April Trust Board
Decisions made	<ul style="list-style-type: none"> • Noted disposition of mental health first aiders

Toby Lewis, Chief Executive

Chair of the Clinical Leadership Executive

For the meeting of the Trust Board scheduled for 7th May 2020